Nephrocare Health Services Ltd
Incorporated in 2010, Nephrocare Health Services Ltd. provides end-to-end dialysis care through a wide network of clinics across India and select international markets.[1]
- Market Cap ₹ 6,779 Cr.
- Current Price ₹ 674
- High / Low ₹ 770 / 445
- Stock P/E
- Book Value ₹ 96.8
- Dividend Yield 0.00 %
- ROCE 5.65 %
- ROE -1.38 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- Stock is trading at 6.97 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of 1.71% over last 3 years.
- Company's cost of borrowing seems high
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Part of Nifty IPO BSE Healthcare BSE IPO BSE 1000
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|
| 284 | 317 | 386 | 436 | 544 | 630 | 651 | |
| 247 | 299 | 348 | 384 | 449 | 541 | 559 | |
| Operating Profit | 38 | 18 | 38 | 52 | 95 | 89 | 93 |
| OPM % | 13% | 6% | 10% | 12% | 17% | 14% | 14% |
| 5 | 4 | 5 | 8 | 16 | 15 | 19 | |
| Interest | 7 | 10 | 15 | 17 | 14 | 50 | 47 |
| Depreciation | 34 | 39 | 41 | 43 | 51 | 58 | 58 |
| Profit before tax | 1 | -28 | -13 | 0 | 45 | -4 | 6 |
| Tax % | 22% | -22% | 20% | -1,668% | 25% | 114% | |
| 1 | -22 | -15 | 4 | 34 | -8 | -1 | |
| EPS in Rs | 5.57 | -110.19 | -77.01 | 18.76 | 164.24 | -0.80 | -14.74 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 17% |
| 3 Years: | 18% |
| TTM: | 16% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 10% |
| TTM: | -130% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 0% |
| 3 Years: | 2% |
| Last Year: | -1% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 2 | 2 | 20 |
| Reserves | 246 | 407 | 392 | 399 | 540 | 951 |
| 140 | 119 | 200 | 182 | 133 | 12 | |
| 32 | 45 | 54 | 82 | 81 | 152 | |
| Total Liabilities | 419 | 572 | 647 | 665 | 757 | 1,135 |
| 159 | 167 | 169 | 219 | 234 | 245 | |
| CWIP | 0 | 2 | 3 | 1 | 4 | 4 |
| Investments | 47 | 110 | 148 | 149 | 212 | 335 |
| 212 | 293 | 328 | 297 | 306 | 551 | |
| Total Assets | 419 | 572 | 647 | 665 | 757 | 1,135 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| 33 | 12 | 11 | 57 | 80 | 133 | |
| -64 | -167 | -75 | -23 | -104 | -299 | |
| 36 | 147 | 63 | -36 | 26 | 256 | |
| Net Cash Flow | 4 | -8 | -0 | -1 | 2 | 90 |
| Free Cash Flow | -18 | -31 | -28 | -18 | -1 | 57 |
| CFO/OP | 51% | 93% | 19% | 120% | 80% | 169% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 98 | 106 | 122 | 116 | 130 | 126 |
| Inventory Days | 65 | 50 | 61 | 51 | ||
| Days Payable | 56 | 52 | 40 | 108 | ||
| Cash Conversion Cycle | 107 | 104 | 143 | 59 | 130 | 126 |
| Working Capital Days | 21 | 48 | 116 | 58 | 62 | 56 |
| ROCE % | -4% | 0% | 3% | 9% | 6% |
Insights
In beta| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Machine Utilization Rate % |
|
|||||
| International Revenue Share % |
||||||
| Number of Active Guests (Patients) guests |
||||||
| Number of Dialysis Machines machines |
||||||
| Number of Dialysis Treatments (Sessions) sessions |
||||||
| Number of PPP (Public-Private Partnership) Clinics clinics |
||||||
| Revenue per Treatment (RPT) INR |
||||||
| Total Number of Dialysis Clinics clinics |
||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
- Transcripts for the investors Earning call held on August 12, 2026.
-
Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements
- Subsidiary acquired dialysis center assets in Abuyog, Leyte, Philippines for PhP 75 million on August 17, 2026.
-
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
- 17th AGM voting results declared on Aug 13, 2026; six resolutions passed, including ESOP 2026 and promoter incentive arrangement.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
- Nephrocare to attend MOSL investor conference on 18 August 2026 in Mumbai.
-
Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements
- Step-down subsidiary acquired Davao City dialysis center assets for PHP 71.8 million on Aug 12, 2026.
Annual reports
Concalls
-
Aug 2026Transcript PPT REC
-
May 2026Transcript PPT REC
-
Feb 2026Transcript PPT REC
Business Profile[1]
Nephrocare Health Services Limited (NHSL) is India’s largest dialysis-care provider offering a full spectrum of renal-care services haemodialysis, peritoneal dialysis, home haemodialysis, dialysis-on-call, dialysis-on-wheels, pharmacy support, diagnostics, and wellness management. It operates through captive hospital-based clinics, standalone centres, and large Public-Private Partnership (PPP) units.